Top Suppliers:I want be here



1236199-60-2

1236199-60-2 structure
1236199-60-2 structure
  • Name: EDO-S101
  • Chemical Name: 7-(5-(bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)-N-hydroxyheptanamide
  • CAS Number: 1236199-60-2
  • Molecular Formula: C19H28Cl2N4O2
  • Molecular Weight: 415.35700
  • Catalog: Research Areas Cancer
  • Create Date: 2018-01-29 19:44:11
  • Modify Date: 2024-01-02 20:53:42
  • EDO-S101 is a pan HDAC inhibitor; inhibits HDAC1, HDAC2 and HDAC3 with IC50 values of 9, 9 and 25 nM, respectively.

Name 7-(5-(bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)-N-hydroxyheptanamide
Synonyms Minomustine
EDO-S101
Description EDO-S101 is a pan HDAC inhibitor; inhibits HDAC1, HDAC2 and HDAC3 with IC50 values of 9, 9 and 25 nM, respectively.
Related Catalog
Target

HDAC6:6 nM (IC50)

HDAC1:9 nM (IC50)

HDAC2:9 nM (IC50)

HDAC3:25 nM (IC50)

HDAC10:72 nM (IC50)

HDAC8:107 nM (IC50)

In Vitro EDOS101 inhibits HDAC activity in rat peripheral blood mononuclear cells (PBMCs) in a cellular assay by approximately 90% one hour after dosing with 10mg/kg i.v. HDAC inhibition in PBMCs could not be increased with higher doses up to 50mg/kg. EDO-S101 triggers apoptosis and shows strong antitumor activity in HL60 and Daudi cells. Initial in vitro experiments in HL60 cells shows an activation of the intrinsic pathway of apoptosis with cleavage of caspases 3, 9 and PARP and a marked reduction of anti-apoptotic proteins XIAP and Mcl-1[1].
In Vivo Intracellular HDAC inhibition of EDO-S101, which occurs rapidly after dosing is at maximum activity already at the lowest dose of 10mg/kg and lasts for about 12-16 hours. Exposure to EDO-S101 causes a strong DNA repair response evidenced by activation of pH2AX and p53 in tumors taken from mice bearing subcutaneous human Burkitt’s lymphoma. Tumors of BL rapidly shrink or are completely eradicated after i.v. administration of EDO-S101[1].
Kinase Assay EDO-S101 is dissolved in DMSO and added to the assay buffer solution. EDO-S101 dilutions of 5 μL of each dilution is added to 50 μL of the reaction mixture including the Fluor de Lys substrate and all of the enzymatic reactions are conducted in duplicate at 37°C for 30 minutes. After enzymatic reactions, 50 μL of 2xHDAC developer is added to each well and fluorescence intensity is measured[1].
Animal Admin Rats: The duration of HDAC inhibition is assessed in 12 female rats after receiving a single dose of either vehicle or EDO-S101 (25mg/kg). Blood samples from EDO-S101 treated rats are collected 1hr, 3hr, 6hr, 16hr and 24hr post dosing (n=2 per time point). Blood sample from vehicle treated rats (n=2) are collected 24hr post dosing[1].
References

[1]. Mehrling T, et al. The Alkylating-HDAC Inhibition Fusion Principle: Taking Chemotherapy to the Next Level with the First in Class Molecule EDO-S101. Anticancer Agents Med Chem. 2016;16(1):20-8.

Molecular Formula C19H28Cl2N4O2
Molecular Weight 415.35700
Exact Mass 414.15900
PSA 70.39000
LogP 4.24660
Storage condition 2-8℃